The International Lecture Series ‘Disease Biology and Molecular Medicine’ brings to Halle’s historic city center renowned researchers from world-leading institutions to share their latest research findings. Set in the grand ballroom of the 19th century-built Stadthaus located at Halle’s main market square, the series is open to the public and aimed at physicians in the region, researchers and students from the medical and natural science faculties of the Martin-Luther-University, as well as experts from local companies and the interested general public.
The lecture series aims to stimulate scientific discussions and to foster a growing network of collaborations in a wide range of biomedical research areas such as genomics, proteomics, cell signaling, human malignancies and chemical biology.
Historischer Saal im Stadtmuseum Halle
Große Märkerstr. 10
06108 Halle (Saale)
07 May 2018; 7 pm
- Professor of Medical Oncology, Oxford Institute for Molecular Pathology, Sir William Dunn School of Pathology. Fellow of Lincoln College, University of Oxford.
His research interests address interactions between the growth promoting function of the ligand, insulin-like growth factor 2, and its non-signalling IGF2 receptor. Genetic models of the IGF system have established the key role of this signalling pathway in tumour growth control. This provides an excellent basis to study how tumour progression is orchestrated in vivo, from pre-malignant changes to established tumours, and how this information can be translated to human cancer prevention, diagnosis and treatment. Current projects include: Structure and function of the IGF2 receptor; functional genetics of Igf2 and Igf2r and tumour growth control; development of soluble human IGF2 receptor as an IGF2 ligand trap and structure and function of the RE-1 silencing repressor transcription complex.
04 December 2017, 7 p.m.
- Structural Genomics Consortium & Oxford University
Chas Bountra is chief scientist at the Oxford branch of the Structural Genomics Consortium (SGC), Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of SGC science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.
12 January 2015, 7 p.m.
- Principal Investigator and CRUK Senior Group Leader
- Oncology Department, University of Oxford
- Old Road Research Campus, Headington, Oxford
- Email: eric.oneilloncology.ox.acuk
Dr Eric O’Neill is a Cancer Research UK Senior Group Leader at the CRUK/MRC Oxford Institute for Radiation Oncology in Oxford and heads the Signalling Group. The overarching aim of his group’s research is to elucidate key stages and molecular players in tumour cell signalling and to use this understanding to enhance treatment strategies and patient response to treatment. Dr O’Neill obtained his BA in microbiology from Trinity College Dublin, Ireland, his MPhil in molecular biology from the University of Umeå, Sweden and his PhD in Cell and Molecular Biology also from the University of Umeå. After a year in Oxford as a Research Associate within the Department of Pharmacology, he was awarded a Marie Curie individual fellowship and completed a five-year post-doctoral position at the Beatson Institute for Cancer Research in Glasgow, before returning to Oxford in 2007 as a Group Leader.